Scarica l'app Stockscreener
47.95
0.74%
0.35
Dopo l'orario di chiusura:
47.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$47.60
Aprire:
$47.53
Volume 24 ore:
808.24K
Relative Volume:
0.55
Capitalizzazione di mercato:
$3.84B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-12.79
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
-0.75%
1M Prestazione:
-7.93%
6M Prestazione:
-5.20%
1 anno Prestazione:
+79.32%
Intervallo 1D:
$47.39
$48.46
Intervallo di 1 settimana:
$45.57
$50.19
Portata 52W:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
47.95 | 3.89B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Iniziato | TD Cowen | Buy |
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Deutsche Bank AG Has $9.48 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
E Fund Management Co. Ltd. Invests $280,000 in Akero Therapeutics, Inc. $AKRO - MarketBeat
527,004 Shares in Akero Therapeutics, Inc. $AKRO Bought by Lord Abbett & CO. LLC - MarketBeat
Akero Therapeutics COO Jonathan Young sells shares worth $538,060 - MSN
Akero Therapeutics (NASDAQ:AKRO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Fox Run Management L.L.C. Makes New $642,000 Investment in Akero Therapeutics, Inc. $AKRO - MarketBeat
Published on: 2025-08-19 16:09:07 - beatles.ru
Andrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Lifesci Capital Has Positive Estimate for AKRO Q3 Earnings - MarketBeat
Jonathan Young Sells 12,500 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Investor Suit Over Liver Drug Trials Permanently Tossed - Law360
Latham Wins Dismissal With Prejudice for Pioneering Liver-Disease Drug Company Akero Therapeutics - Latham & Watkins LLP
Akero Defeats Investor Lawsuit Over Liver Drug Trial’s Design - Bloomberg Law News
Analysts Divided on Akero Therapeutics and Kodiak Sciences: AKRO and KOD Ratings Revealed - AInvest
Informed Momentum Co LLC Acquires New Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
20,253 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Aigen Investment Management LP - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.8%Here's Why - MarketBeat
Akero Therapeutics Inc. Shows Risk Reward Favoring Upside2025 Volume Leaders & AI Enhanced Trading Alerts - kangso.co.kr
Akero Therapeutics shares fall 3.81% after-hours following publication of Phase 2b HARMONY trial results in The Lancet. - AInvest
Reversal Confirmed Akero Therapeutics Inc. Stock Rallies Above MAJuly 2025 Institutional & High Conviction Buy Zone Alerts - sundaytimes.kr
Akero Therapeutics shares fall 2.85% intraday as investors take profits and insiders sell stock. - AInvest
Published on: 2025-08-15 12:12:33 - metal.it
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial - TipRanks
EFX's 96-Week HARMONY Trial: A Paradigm Shift in MASH Treatment and a High-Conviction Buy Case for AKRO - AInvest
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH - GlobeNewswire
Nearly Half of Patients See Liver Fibrosis Improvement: Akero's EFX Drug Shows Promise in 96-Week MASH Study - Stock Titan
Akero Therapeutics: Contrarian Opportunity Amid FDA Approval and Insider Selling - AInvest
Reversing Akero Therapeutics Contrarian Buy Rating to Contrarian Sell Rating - AInvest
Akero Therapeutics: Why I'm Reversing My Contrarian Buy Rating To A Contrarian Sell Rating - Seeking Alpha
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Zacks Investment Research
Insider Selling and Market Confidence at Akero Therapeutics: A Balancing Act of Strategy and Optimism - AInvest
Akero Therapeutics Insider Sold Shares Worth $1,457,596, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics Insider Sold Shares Worth $597,326, According to a Recent SEC Filing - MarketScreener
Akero Therapeutics COO Young sells $597k in shares By Investing.com - Investing.com Australia
Akero Therapeutics COO Young sells $597k in shares - Investing.com
Akero Therapeutics CEO Cheng sells $1.46 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Cheng sells $1.46 million in stock - Investing.com India
Akero Therapeutics Executives Sell Shares - TradingView
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Sentiment Turns Positive on Akero Therapeutics Inc. — Reversal AheadTrade Performance Summary & Weekly Momentum Picks - metal.it
Vivo Capital LLC Invests $8.14 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics director Henderson sells $142k in shares By Investing.com - Investing.com Nigeria
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akero Therapeutics Inc Azioni (AKRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Young Jonathan | Chief Operating Officer |
Aug 12 '25 |
Option Exercise |
21.10 |
12,500 |
263,750 |
209,984 |
| Young Jonathan | Chief Operating Officer |
Aug 12 '25 |
Sale |
47.79 |
12,500 |
597,326 |
197,484 |
| Cheng Andrew | President and CEO |
Aug 11 '25 |
Sale |
48.59 |
30,000 |
1,457,596 |
490,757 |
| Henderson Jane | Director |
Aug 12 '25 |
Option Exercise |
7.01 |
3,000 |
21,027 |
12,398 |
| Henderson Jane | Director |
Aug 12 '25 |
Sale |
47.46 |
3,000 |
142,371 |
9,398 |
2.44%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):